obesity drug news today glp-1 october 21 2025 Market New Daily GLP-1 Weight Loss

Anagliptin, which is only approved since 2012 in the Japanese market, seems to have serum lipid-lowering and anti-atherogenic actions as well, which makes it unique among the gliptins approved so far (101, 102)

GIP/GLP-1 co-agonists, developed by merging the respective peptide sequences, potently lower body weight in rodents and humans 27,28

How do I get started on Ro?

[DOI] [PMC free article] [PubMed] [Google Scholar] 162.Yancy W.S., Olsen M.K., Guyton J.R., Bakst R.P., Westman E.C

Diabetes (2021) 70:192937

The protective cardiovascular effects of GLP-1RAs can be through improving glycemic control, as reducing HbA1c can improve blood pressure, body weight, hyperlipoproteinemia, and inflammation